| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CLAP; mE10; CIPER; c-E10; CARMEN |
| WB Predicted band size | 26 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human BCL10 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于BCL10抗体的关键文献摘要：
1. **"BCL10 mutation in lymphoma"**
- **作者**: Uno, J., et al.
- **摘要**: 研究通过免疫组化结合BCL10抗体，揭示了BCL10基因突变与黏膜相关淋巴组织(MALT)淋巴瘤的关联，证实其异常表达可作为诊断标志物。
2. **"Role of BCL10 in NF-κB activation"**
- **作者**: Ruland, J., et al.
- **摘要**: 利用BCL10特异性抗体进行Western blot和共沉淀实验，阐明BCL10通过CARMA1信号复合体激活NF-κB通路，调控T细胞免疫反应。
3. **"BCL10 expression in MALT lymphoma"**
- **作者**: Willis, T.G. & Wotherspoon, A.C.
- **摘要**: 通过BCL10抗体免疫染色，发现核内BCL10聚集与t(11;18)染色体易位相关，为MALT淋巴瘤的分子分型提供依据。
4. **"BCL10 antibody applications in signaling studies"**
- **作者**: Ye, H. & Chuang, S.S.
- **摘要**: 比较多种BCL10抗体的特异性，验证其在流式细胞术及免疫荧光中的适用性，优化了BCL10蛋白亚细胞定位分析方法。
*注：以上文献标题及内容为示例性概括，实际引用需核对原文信息。建议通过PubMed或Web of Science以"BCL10 antibody"为关键词检索最新研究。*
**Background of BCL10 Antibodies**
BCL10 (B-cell lymphoma 10) is a ubiquitously expressed adaptor protein involved in immune signaling, inflammation, and apoptosis. It plays a critical role in activating the NF-κB pathway via interactions with proteins like CARMA1 and MALT1. forming the CBM complex, which regulates lymphocyte activation and antigen receptor signaling. Dysregulation of BCL10 is linked to malignancies, particularly mucosa-associated lymphoid tissue (MALT) lymphomas, and immune disorders.
BCL10 antibodies are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies enable detection of BCL10 in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), helping to assess its involvement in diseases. For instance, abnormal BCL10 expression or truncation due to chromosomal translocations (e.g., t(1;14) in MALT lymphoma) is a diagnostic marker.
Research using BCL10 antibodies has also clarified its dual role: promoting apoptosis in certain contexts while driving NF-κB-mediated cell survival in others. Additionally, studies in knockout models highlight its necessity for immune responses. Therapeutic strategies targeting BCL10 or its interactions, such as protease inhibitors blocking MALT1 activity, are under investigation. Thus, BCL10 antibodies remain vital for advancing insights into immune regulation, oncogenesis, and targeted therapies.
×
